beneficial in clinical practice fail to reduce exacerbations or improve quality of life in regulatory studies. The heterogeneity of bronchiectasis is almost its characteristic feature and remains the greatest challenge both in clinical care and in designing and interpreting research. Patients with bronchiectasis urgently need proven therapies and better pathways of care. This Monograph brings together a team of leading global experts to discuss the many challenges and opportunities for the disease. Covering topics from pathophysiology, diagnostic testing and management through to critical research topics, such as trial end-points, this book is essential reading for anyone caring for those with the disease or conducting research. Disclosures: J.D. Chalmers reports receiving the following, outside the submitted work: grants for research into COPD and personal fees from GlaxoSmithKline, Boehringer Ingelheim and Pfizer grants for research into COPD from AstraZeneca grants for research into bronchiectasis and personal fees from Bayer Healthcare and Grifols and personal fees for consulting from Napp. E. Polverino reports receiving honoraria for speeches from Bayer, Ismed, Grifols and Chiesi, during the current work. E. Polverino received grants and personal fees from Chiesi, outisde the submitted work. S. Aliberti reports receiving the following outside the submitted work: grants and personal fees from Bayer Healthcare, Aradigm Corporation, Grifols, Chiesi and INSMED personal fees from AstraZeneca, Basilea, Zambon, Novartis, Raptor, Actavis UK Ltd and Horizon. xiv
Previous Page Next Page